Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the successful completion of a multi-year study on the application of cold atmospheric plasma (CAP) in the lung. The study data will be submitted for publication in a renowned scientific journal, marking a significant milestone for the company and the field of pneumology.
The research focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine. Results confirmed the potential of cold plasma as a physical, non-pharmacological treatment option for severe infectious lung diseases. The data demonstrated a clearly defined therapeutic safety window and a complete reduction of pathogenic germs in lung epithelial models.
Key validation work was conducted ex vivo on vital lungs in collaboration with Saarland University and Hannover Medical School. The isolated, ventilation- and perfusion-capable lung model used realistically reflects key physiological characteristics of the human lung, enabling reproducible investigations on vital organ tissue.
Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated: "By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems of the human body."
Based on the study results, Viromed's technology has already been used in a university setting for a severe pulmonary individual case in a human patient. Following approval by the responsible ethics committee, a university hospital with a department specializing in lung and transplantation medicine treated a patient in connection with a lung transplant and massive complications. The use of cold plasma was very successful, and according to the treating physicians, the observed positive clinical course was exceptional. The hospital plans to publish the case in the near term, and further severely ill patients with a high risk of fatal outcome are undergoing treatment.
Viromed sees clear indications that cold plasma technology will fundamentally change pneumology. While classical pharmacological therapies are increasingly limited by the development of resistance, cold plasma as a physical mode of action opens up a new therapeutic dimension, also for the prevention of severe pulmonary infections. Looking ahead, further applications are moving into clinical research, such as intracardiac use in operations for bacterial endocarditis before implantation of a valve prosthesis, or application in the thorax for bacterial pleural empyema.
This development could have significant implications for intensive care medicine, potentially reducing reliance on antibiotics and addressing the growing challenge of antimicrobial resistance. For leaders in business and technology, the advancement of cold plasma technology represents a novel therapeutic approach with substantial market potential, particularly as Viromed positions itself as the first and only company addressing this global market. The company's technology could impact treatment protocols for VAP, a condition affecting a large number of ICU patients worldwide, and may extend to other infectious diseases in sensitive organ systems.
For more information, visit Viromed Medical AG.
